Advertisement
Advertisement
U.S. markets open in 5 hours 36 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Hillstream BioPharma, Inc. (HILS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8900+0.1341 (+17.74%)
At close: 04:00PM EDT
0.8600 -0.03 (-3.37%)
After hours: 07:52PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close0.7559
Open1.0800
Bid0.0000 x 3100
Ask0.0000 x 1000
Day's Range0.8700 - 1.1200
52 Week Range0.6500 - 4.2400
Volume7,534,425
Avg. Volume1,435,893
Market Cap10.328M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3910
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for HILS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Hillstream BioPharma, Inc.
    Technical Assessment: Bearish in the Intermediate-TermWe have not talked much about small-cap stocks as they have steadily underperformed the S&P 500 since February 2021 and the S&P MidCap 400 since January 2021. Both the Russell 2000 (IWM) and the S&P SmallCap 600 (SML) peaked in November 2021 and have been tracing out lower lows and lower highs ever since. At the June 16 closing low, the IWM had cratered 32% while the SML had given up 26%. Interestingly, the hyper-revenue-growth/no-EPS stocks peaked in late 2020 and early 2021, well before the small-caps. The Nasdaq, QQQs and the S&P 500 all peaked in late 2021/early 2022.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments

    Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint InhibitorsBRIDGEWATER, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced a collaboration with Sapien Biosciences to evaluat

  • Benzinga

    Why Hillstream BioPharma Shares Are Trading Higher Today?

    Hillstream BioPharma Inc (NASDAQ: HILS) shares are trading higher after it authorized a share repurchase program to acquire up to $1 million in common stock. As of March 31, Hillstream had approximately $11.1 million in cash and 11.4 million shares of common stock. "We have demonstrated strong execution and, as a result, have seen significant advancement of our pipeline," said Randy Milby, Hillstream's CEO. "The current market situation allows us to capture additional value for all investors thr

  • GlobeNewswire

    Hillstream BioPharma Announces Share Repurchase Program

    BRIDGEWATER, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced that its Board of Directors has authorized a share repurchase program to acquire up to $1 million of the Company's common stock. The Company may purcha

Advertisement
Advertisement